Next Article in Journal
Effect of a Mobile App-Based Exercise Program on Diastasis Recti Abdominis, Muscle Strength, Anthropometric Measures, and Satisfaction Among Post-Cesarean Primiparous Mothers: A Randomized Controlled Trial
Previous Article in Journal
Comparative Effectiveness of Kyphoplasty and Radiation with or Without Radiofrequency Ablation in Spinal Metastases from Lung Cancer
Previous Article in Special Issue
Obesity, Knowledge, and Perceived Risk: Insights from the ObeCare Project Across Italian Territorial Pharmacies
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Healthcare
Volume 13
Issue 23
10.3390/healthcare13233102
healthcare-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Exploring Adults’ Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study

by
Shukri Adam
1,
Fatma M. Ibrahim
2,*,
Eman Abdelaziz Ahmed Dabou
3,
Sneha Pitre
1,
Rania Aiman
1 and
Shimaa AbdelSamad
4
1
RAK College of Nursing, RAK Medical and Health Science University, RAS Al-Khaimah P.O. Box 11172, United Arab Emirates
2
Faculty of Nursing, Mansoura University, Mansoura 35516, Egypt
3
Faculty of Nursing, Jordan University of Science and Technology, Irbid 22110, Jordan
4
Faculty of Nursing, Alexandria University, Alexendria 21568, Egypt
*
Author to whom correspondence should be addressed.
Healthcare 2025, 13(23), 3102; https://doi.org/10.3390/healthcare13233102
Submission received: 23 September 2025 / Revised: 2 November 2025 / Accepted: 24 November 2025 / Published: 28 November 2025
(This article belongs to the Special Issue Obesity and Overweight: Prevention, Causes and Treatment)
Browse Figure
Versions Notes

Highlights

What are the main findings?
  • Among 120 adults (mean age 42 ± 13 years; 50.8% male), 91.7% reported weight loss after initiating tirzepatide.
  • Average Weight Efficacy Lifestyle (WEL) total score was 91 ± 34 (0–180 scale); higher WEL was observed in females, employed participants, those with coverage, and early in treatment.
  • Interviews (n = 15) described high satisfaction with weight loss, better sleep/energy/mood, and mostly mild/transient gastrointestinal effects.
  • Findings support pairing pharmacotherapy with behavioral support and addressing affordability/coverage to sustain benefits.
What is the implication of the main finding?
  • Findings support the integration of behavioral support alongside tirzepatide pharmacotherapy and highlight the importance of treatment affordability and coverage. Prospective longitudinal studies are warranted to assess the durability of self-efficacy and health outcomes and to test strategies that optimize adherence and equitable access.

Abstract

Background: Obesity confers substantial cardiometabolic risk. Tirzepatide, a once-weekly dual GIP/GLP-1 receptor agonist, produces dose-dependent weight loss in trials, but real-world patient-reported experiences are under-described. We evaluated real-world self-efficacy and experiences with tirzepatide in community settings. Methods: Explanatory sequential mixed-methods study of adults aged 18–59 years using tirzepatide for weight management. We collected a quantitative survey (demographics; medication use; 20-item Weight Efficacy Lifestyle Questionnaire [WEL]) followed by purposive semi-structured interviews. Associations between WEL and participant characteristics were tested a priori (two-tailed α = 0.05). Results: Among 120 participants (50.8% male; mean age 42 ± 13 years), 91.7% reported weight loss and 85.8% had <6 months’ exposure. WEL total was 91 ± 34. Higher WEL was observed in females, employed participants, those with insurance coverage versus self-pay, during early months of therapy, and among those with prior weight-loss attempts (all p < 0.05). Interviews (n = 15) indicated high satisfaction, improved sleep/energy, mood, and confidence; gastrointestinal effects were usually mild/transient. Interpretation: In routine care, tirzepatide use was associated with high eating self-efficacy and positive patient-reported outcomes. Variation by coverage and duration suggests value in pairing pharmacotherapy with behavioral support and addressing affordability to sustain benefits.

1. Introduction

Obesity confers substantial cardiometabolic and psychosocial burden, and many adults achieve only modest, un-sustained loss with lifestyle measures alone [1]. Incretin-based pharmacotherapy has expanded treatment options, particularly glucagon-like peptide 1 (GLP 1) receptor agonists that enhance satiety, modulate glycaemia, and support weight reduction [2,3]. Tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and GLP 1 receptor agonist, reduces energy intake and improves glycemic control via complementary mechanisms [4,5].
Regulatory approvals include type 2 diabetes (U.S. FDA, May 2022) [6] and chronic weight management in adults with obesity or overweight plus a weight-related condition (U.S. FDA, November 2023) [7] as an adjunct to diet and activity. Randomized trials demonstrate dose-dependent weight loss (e.g., SURPASS-2 in type 2 diabetes; SURMOUNT-1/3 in obesity), with emerging evidence of greater weight reduction versus semaglutide in some populations [3,4,8].
Yet little is known about adults’ lived experiences in community settings, including perceived benefits, side effect trajectories, and eating self-efficacy in everyday contexts. Exit interviews from SURMOUNT-4 and digital-engagement studies offer insights but may not generalize to routine care [8,9]. Real-world perspectives are essential to contextualize trial findings, inform shared decision-making, and optimize long-term effectiveness. Consequently, the aim of the study was to characterize real-world patient-reported experiences with tirzepatide for weight management using an explanatory sequential mixed-methods design, quantifying eating self-efficacy and weight change and contextualizing these data with semi-structured interviews.

2. Materials and Methods

2.1. Study Design

We used an explanatory sequential mixed-methods design [10]: an initial quantitative survey followed by qualitative interviews to explain quantitative patterns. Integration occurred at interpretation through joint displays and meta-inferences. The study was approved by the Ministry of Health and Prevention Research Ethics Committee (MOHAP/REC/2025/14-2025-F-N). All participants provided written informed consent.

2.2. Setting and Participants

Adults were recruited from community locations in Ras Al Khaimah Emirate (malls, marketplaces, institutions, homes). Trained staff approached potential participants, confirmed eligibility, and obtained written informed consent prior to enrollment.

2.3. Eligibility Criteria

Inclusion: age 18–59 years; current or prior tirzepatide use for weight management; body mass index (BMI) ≥ 30 kg/m2 or ≥27 kg/m2 with ≥1 weight-related comorbidity (per indication). Exclusion: type 1 diabetes; contraindications per label (e.g., medullary thyroid carcinoma/MEN2); concomitant enrollment in another weight-loss trial; severe psychiatric/eating disorders impairing adherence or consent.

2.4. Sample Size and Sampling

A planned target of n = 267 (Raosoft: population ≈ 2000; confidence level 90%; margin of error 5%) was not reached due to time/resource constraints; recruitment during April 2025 yielded n = 120 complete quantitative cases. For the qualitative phase, a purposive subsample (n = 15) maximized variation by sex, treatment duration, weight-loss category, and WEL scores.

2.5. Outcomes

Primary outcomes: (a) self-reported percent weight loss since initiating tirzepatide (none, <5%, 5–10%, >10%); (b) eating self-efficacy (WEL total, 0–180). Secondary outcomes: item-level WEL responses; associations of WEL with demographics/clinical characteristics (age, sex, employment, insurance/coverage, BMI, duration of use, prior attempts).

2.6. Measures (Instruments)

Weight Efficacy Lifestyle Questionnaire (WEL): Total of 20 items rated 0 (“not confident”) to 9 (“very confident”); total 0–180 with higher scores indicating greater self-efficacy. Internal consistency for the total score is excellent (Nauck et al., 2022) [11]. We report total and item-level means.
Semi-structured interview guide: Interviews explored motivations, routines/self-management, side effects and dose titration, facilitators/barriers to adherence, and perceived changes in appetite, sleep, mood, activity, and overall satisfaction (Supplementary File S1).

2.7. Data Collection Procedures

Field team and steps to minimize bias: Data collection was conducted by two RN/PhD-trained researchers (approximate age range (25–36) years) who were not involved in participants’ clinical care. Interviewers followed standardized scripts, used neutral prompts, and conducted surveys/interviews privately to reduce social desirability and interviewer bias. Team members received protocol-specific training and practiced mock interviews; periodic debriefs were used to ensure fidelity and reflexivity.

2.8. Quantitative Analysis

Analyses used SPSS 29. Continuous variables are summarized as mean ± SD or median (IQR); categorical variables as n (%). Group differences for WEL used independent-samples t-tests (two groups) and one-way ANOVA (≥3 groups) with post hoc comparisons as appropriate. Assumptions were examined (Kolmogorov–Smirnov); we report 95% confidence intervals and two-tailed α = 0.05. Pearson correlations related WEL with age and BMI. Missing data (<5% per variable) were handled via listwise deletion.

2.9. Qualitative Analysis

Two analysts conducted reflexive thematic analysis (Braun & Clarke’s six phases). Coding discrepancies were resolved by discussion; an audit trail documented analytic decisions. A brief reflexive statement is provided in Supplementary File S1.

2.10. Mixed-Methods Integration

Quantitative results informed purposive sampling and interview prompts (connecting); we merged quantitative and qualitative data in joint displays to juxtapose WEL/weight-loss patterns with qualitative themes, generating integrative insights.

3. Results

3.1. Participant Characteristics

Interview subsample characteristics. The purposive interview subsample (n = 15) was selected to maximize variation in sex, treatment duration, self-reported weight-loss category, and WEL scores. A total of 120 adults (50.8% male; mean age 42 ± 13 years; 95% CI 39.7 to 44.3) were included. Most participants reported some weight loss (110/120; 91.7%; 95% CI 85.3% to 95.4%) after starting tirzepatide. Mean BMI at survey was 25.74 ± 3.96 kg/m2. Most had used tirzepatide for <6 months (85.8%). The mean WEL total score was 91 ± 34 (95% CI 84.9 to 97.1); Table 1 Continuous variables are presented as mean (standard deviation) with units; categorical variables as n (%).

3.2. Weight Efficacy Lifestyle (WEL) Items

Participants’ WEL item means generally clustered around 4–5 on a 0–9 scale, indicating moderate confidence across emotional and situational eating contexts, with notable strengths for resisting eating under social pressure, fatigue, and celebratory situations, and relatively lower confidence when highly palatable foods were available or under negative affect (Table 2).

3.3. Associations Between WEL Total and Participant Characteristics

Most participants reported some weight loss (110/120; 91.7%; 95% CI 85.3% to 95.4%) after starting tirzepatide. Mean BMI at survey was 25.74 ± 3.96 kg/m2. Most had used tirzepatide for <6 months (85.8%). The mean WEL total score was 91 ± 34 (95% CI 84.9 to 97.1). Table 3 key comparative estimates (differences in means, 95% CI): Female–Male (WEL): 7.0 (95% CI −5.1 to 19.1). Employed–Unemployed (WEL): 6.0 (95% CI: −4.9 to 16.9).
Exploratorily, given that 85.8% of participants were within the first 6 months of therapy, the distribution of percent weight-loss categories across treatment duration strata could not be robustly evaluated (sparse cells precluding a valid trend test). Nonetheless, the higher early-phase WEL scores suggest an initial motivational “lift” that may attenuate over time without structured support.

3.4. Correlations of WEL with Age and BMI

Age showed a positive correlation with WEL total (r = 0.239, p = 0.009). In contrast, BMI did not (r = 0.004, p = 0.963), indicating that greater weight-control self-efficacy was associated with older age but not current BMI. Table 4, Figure 1 Qualitative findings (n = 15 interviews) . Four cross-cutting themes emerged: (1) perceived benefits and satisfaction; (2) side effect trajectory and self-management; (3) psychosocial impact and emotional well-being; and (4) motivation, adherence, and context; Table 5.

3.5. Four Cross-Cutting Themes Emerged (with Typical Variation)

Perceived benefits and satisfaction. Most participants reported high satisfaction with tirzepatide due to visible weight loss, improved appearance, and self-confidence. Many described greater energy and easier mobility/exercise (less breathlessness/fatigue). Several noted better sleep (faster sleep onset, deeper sleep). A minority reported slower-than-expected progress or limited change in activity.
Side effect trajectory and self-management. Initial GI-type symptoms (e.g., nausea, dizziness, headache, irritability) were common, generally mild to moderate and transient, sometimes recurring with dose increases. Most participants reported that side effects did not meaningfully interfere with daily activities beyond the first week; a few described brief activity adjustments (more rest, lighter schedules).
Psychosocial impact and emotional well-being. Many described improved mood, self-acceptance, and optimism; several linked these to weight changes and positive feedback from others. A subset reported no mental health change despite weight loss, underscoring heterogeneity in psychological response.
Motivation, adherence, and context. Common motivations included difficulty losing weight with traditional methods, health concerns (e.g., joint pain, diabetes risk), and appearance-related goals. Adherence facilitators included early weight changes, social encouragement, and insurance coverage; barriers included out-of-pocket costs and dose-related side effects. Many participants emphasized simple routines (timing injections, hydration, and smaller portions) as practical adherence supports.

3.6. Integration of Quantitative and Qualitative Findings

Early phase lift, later attenuation, financial context matters, and heterogeneous psychosocial response. These integrated insights suggest ongoing behavioral support and affordability measures alongside pharmacotherapy. A summary of key quantitative and qualitative integrations is provided. Early phase lift, later attenuation: Highest WEL scores in <1-month users, coupled with interview accounts of early motivation/optimism diminishing for some overtime, suggesting a need for ongoing behavioral support as treatment progresses. Financial context matters: Lower WEL among those paying out-of-pocket aligned with narratives about cost stress affecting confidence and adherence.
Heterogeneous psychosocial response: Quantitative differences by sex/employment echoed themes of social support/structure facilitating self-regulation, while qualitative heterogeneity in mood benefits cautions against assuming uniform psychological gains.

4. Discussion

This mixed-methods study adds real-world evidence to the tirzepatide literature by centering adults’ lived experiences alongside quantitative indicators of eating self-efficacy. Participants reported improvements across physical, emotional, and social domains, consistent with pharmacologic mechanisms and trial outcomes [2,3,4,8,9,12,13].

Principal Findings in Context

Participants demonstrated generally strong weight-efficacy beliefs across social and affective situations, aligning with reports that GLP-1-based therapies can attenuate appetite and reward-related eating and support more mindful eating patterns [13]. Qualitative accounts in semaglutide users similarly describe reduced urges to eat under stress, suggesting a class effect that may facilitate adherence to lifestyle prescriptions. Notably, our item-level profile showed comparatively lower confidence for anxiety, depression, cravings, parties, and high-calorie availability, echoing evidence that hedonic cues can remain potent even with pharmacotherapy and that targeted behavioral strategies are needed in parallel [14]. Prior work has also observed that emotional-eating improvements are not universal under GLP-1 therapy [15], underscoring inter-individual variability and the value of adjunct behavioral support. Sociodemographic and access gradients were also analyzed.
Women reported higher self-efficacy than men, consistent with the literature showing stronger engagement with health-promoting behaviors among women in structured weight management [16,17]. Employment was associated with higher self-efficacy plausibly through greater routine, resources, or social structure that support health behaviors [18]. Insurance coverage patterns also mapped onto higher self-efficacy versus self-pay, aligning with research on financial toxicity and medication adherence: out-of-pocket costs can erode motivation and persistence [19]. Together, these findings point to modifiable system-level levers (coverage, counseling access) to bolster treatment success. Treatment exposure and prior attempts: Highest self-efficacy in the earliest exposure window may reflect a “honeymoon” period of optimism that attenuates without reinforcement, arguing for planned dose-titration support, side effect management, and periodic skill “boosters” to sustain gains [20,21]. Participants with prior diet-based attempts showed greater self-efficacy than those reporting fasting-only or activity-only approaches, mirroring evidence that structured, sustainable nutrition strategies better generalize to daily coping [22,23].
Patient-reported benefits beyond weight: Many participants reported improved sleep quality, energy, and mood, and findings consistent with data indicating that weight reduction and GLP-1 therapies can lead to better sleep (including OSA) and improved quality of life [24,25]. Still, variability was common: some reported unchanged activity or energy, highlighting the roles of baseline comorbidity, life demands, and the need for tailored behavioral activation [26]. Side effects were typically mild-to-moderate and transient, consistent with trial and real-world reports, yet dose escalations occasionally amplified symptoms, reinforcing the value of anticipatory guidance and pragmatic titration.
Implications for practice and policy:
  • Pair tirzepatide with structured behavioral support targeting hedonic cues (parties, cravings, high-calorie availability) and negative affect (stress, loneliness).
  • Plan adherence supports at the 1–6-month mark (digital check-ins, skills refreshers, dose-escalation side effect troubleshooting).
  • Address affordability and coverage barriers to mitigate financial stress that may undermine persistence.
  • Track patient-reported outcomes (sleep, mood, energy, social functioning) alongside weight and metabolic markers.
Strengths and limitations. Strengths include an explanatory sequential design, standardized self-efficacy measurement, and triangulation with qualitative interviews. Limitations include convenience sampling from a single region, one-group pre–post design (no control), reliance on self-report, and short-term follow-up; these limit causal inference and generalizability.

5. Conclusions

In community settings, adults using tirzepatide reported broadly positive experiences, higher eating self-efficacy, and perceived gains in sleep, energy, and mood alongside typically transient gastrointestinal effects. Variation by treatment duration and affordability highlights the importance of pairing pharmacotherapy with structured behavioral support and addressing coverage to sustain benefits.

5.1. Future Research

Key focus domains are as follows: (a) long-term studies designed to follow self-efficacy, adherence, and patient-reported outcomes (PROs) over at least 12 months; (b) practical trials of behavioral interventions that directly address stress reactivity and hedonic triggers through the context of oftirzepatide treatment; (c) equity-informed assessments of coverage models and their effects on persistence of treatment; and (d) studies aimed at mechanisms that connect changes in reward-based eating with changes in affect.

5.2. Data Sharing

De-identified quantitative data, the interview guide, and analysis code will be shared on reasonable requests to the corresponding author, subject to institutional approvals and confidentiality.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/healthcare13233102/s1, File S1: Semi-structured interview guide.

Author Contributions

(CRediT) and data access/verification Conceptualization: F.M.I.; Methodology: F.M.I. and S.A. (Shukri Adam); Investigation: S.P.; Formal Analysis: E.A.A.D. and F.M.I.; Writing—original draft: S.A. (Shimaa AbdelSamad) and F.M.I.; Writing—review and editing: F.M.I., S.A. (Shimaa AbdelSamad) and S.P.; Data access and verification: F.M.I. and E.A.A.D. had access to raw data. Both verified the underlying data and took responsibility for its accuracy and integrity. R.A. revised the comments with the team. All authors have read and agreed to the published version of the manuscript.

Funding

The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data and had final responsibility for the decision to submit it for publication.

Institutional Review Board Statement

The study adhered to the Declaration of Helsinki. The protocol was approved by the Ministry of Health and Prevention Research Ethics Committee (MOHAP/REC/2025/14-2025-F-N, date 28 January 2025).

Informed Consent Statement

All participants provided written informed consent. To protect confidentiality, data were de-identified and stored on encrypted, access-restricted servers. Patients and the public were not involved in the design, conduct, reporting, or dissemination plans of this research.

Data Availability Statement

The data presented in this study are available on request from the corresponding author due to privacy concerns.

Acknowledgments

We suggest that the author Ghada Shahrour be acknowledged in the acknowledgements section. Declaration of generative AI in the writing process. During the preparation of this work, the authors used ChatGPT (OpenAI, https://chatgpt.com/) to assist with language editing, reference formatting, and table structuring. After using this tool, the authors reviewed and edited the content as needed and took full responsibility for the content of the publication. No AI systems were used for data collection, statistical analysis, or image creation/manipulation, and no AI tool is listed as an author.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. World Health Organization. Obesity and Overweight: Fact Sheet. 1 March 2024. Available online: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (accessed on 10 February 2025).
  2. Chavda, V.P.; Ajabiya, J.; Teli, D.; Bojarska, J.; Apostolopoulos, V. Tirzepatide: A New Era of Dual-Targeted Treatment for Diabetes and Obesity—A Mini-Review. Molecules 2022, 27, 4315. [Google Scholar] [CrossRef] [PubMed]
  3. Wadden, T.A.; Chao, A.M.; Machineni, S.; Kushner, R.; Ard, J.; Srivastava, G.; Halpern, B.; Zhang, S.; Chen, J.; Bunck, M.C.; et al. Tirzepatide After Intensive Lifestyle Intervention in Adults with Overweight or Obesity: The SURMOUNT-3 Phase 3 Trial. Nat. Med. 2023, 29, 2909–2918. [Google Scholar] [CrossRef] [PubMed]
  4. Rubino, D.M.; Riddle, M.C.; Cefalu, W.T.; Rosenstock, J.; Bunck, M.C.; Frias, J.P. Effect of Tirzepatide vs. Semaglutide Once Weekly on Glycemic Control and Body Weight in Type 2 Diabetes (SURPASS-2). N. Engl. J. Med. 2021, 385, 503–515. [Google Scholar] [CrossRef]
  5. Farzam, K.; Patel, P. Tirzepatide. In StatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, USA, 2024. Available online: https://www.ncbi.nlm.nih.gov/books/NBK585056/ (accessed on 10 February 2025).
  6. U.S. Food & Drug Administration. FDA Approves Mounjaro (Tirzepatide) Injection for Adults with Type 2 Diabetes. 13 May 2022. Available online: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-mounjaro (accessed on 10 February 2025).
  7. U.S. Food & Drug Administration. FDA Approves New Medication for Chronic Weight Management. 8 November 2023. Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management (accessed on 10 February 2025).
  8. Jastreboff, A.M.; Aronne, L.J.; Ahmad, N.N.; Wharton, S.; Connery, L.; Alves, B.; Kiyosue, A.; Zhang, S.; Liu, B.; Bunck, M.C.; et al. Tirzepatide Once Weekly for the Treatment of Obesity. N. Engl. J. Med. 2022, 387, 205–216. [Google Scholar] [CrossRef] [PubMed]
  9. Aronne, L.J.; Horn, D.B.; le Roux, C.W.; Ho, W.; Falcon, B.L.; Gomez Valderas, E.; Das, S.; Lee, C.J.; Glass, L.C.; Senyucel, C.; et al. Tirzepatide as Compared with Semaglutide for Weight Reduction in Adults with Obesity. N. Engl. J. Med. 2025; Online ahead of print. [Google Scholar] [CrossRef]
  10. Clark, M.M.; Abrams, D.B.; Niaura, R.S.; Eaton, C.A.; Rossi, J.S. Self-Efficacy in Weight Management. J. Consult. Clin. Psychol. 1991, 59, 739–744. [Google Scholar] [CrossRef] [PubMed]
  11. Nauck, M.A.; Meier, J.J. Incretin Hormones: Their Role in Health and Disease. Diabetes Obes. Metab. 2022, 24 (Suppl. S2), 5–21. [Google Scholar] [CrossRef] [PubMed]
  12. Arillotta, D.; Floresta, G.; Papanti Pelletier, G.D.; Guirguis, A.; Corkery, J.M.; Martinotti, G.; Schifano, F. Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: A Mixed-Methods Study. Brain Sci. 2024, 14, 617. [Google Scholar] [CrossRef] [PubMed]
  13. Pierret, A.C.; Benton, M.; Sen Gupta, P.; Ismail, K. A qualitative study of the mental health outcomes in people being treated for obesity and type 2 diabetes with glucagon-like peptide-1 receptor agonists. Acta Diabetol. 2025, 62, 731–742. [Google Scholar] [CrossRef] [PubMed]
  14. Kakoschke, N.; Henry, B.A.; Cowley, M.A.; Lee, K. Tackling Cravings in Medical Weight Management: An Integrated Approach. Nutrients 2024, 16, 3238. [Google Scholar] [CrossRef] [PubMed]
  15. van Ruiten, C.C.; ten Kulve, J.S.; van Bloemendaal, L.; Nieuwdorp, M.; Veltman, D.J.; IJzerman, R.G. Eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: A secondary analysis of a randomized trial. Psychoneuroendocrinology 2022, 137, 105667. [Google Scholar] [CrossRef] [PubMed]
  16. Guglielmi, V.; Dalle Grave, R.; Leonetti, F.; Solini, A. Female Obesity: Clinical and Psychological Assessment. Front. Endocrinol. 2024, 15, 1349794. [Google Scholar] [CrossRef] [PubMed]
  17. Johnson, H.; Huang, D.; Liu, V.; Ammouri, M.A.; Jacobs, C.; El-Osta, A. Digital Engagement and Weight Loss in GLP-1 Therapy Users. J. Med. Internet Res. 2025, 27, e69466. [Google Scholar] [CrossRef] [PubMed]
  18. Carr, L.T.B.; Johnson, V.R. Epidemiology and Significance of Obesity. In The Handbook of Health Behavior Change; Springer: Berlin/Heidelberg, Germany, 2024. [Google Scholar]
  19. Rodbard, H.W.; Barnard-Kelly, K.; Pfeiffer, A.F.; Mauersberger, C.; Schnell, O.; Giorgino, F. Practical Strategies to Manage Obesity in Type 2 Diabetes. Diabetes Obes. Metab. 2024, 26, 2029–2045. [Google Scholar] [CrossRef] [PubMed]
  20. Takyi, A.K.; Gaffey, R.H.; Shukla, A.P. Optimizing the Efficacy of Anti-Obesity Medications: A Practical Guide to Personalizing Incretin-Based Therapies. Curr. Treat. Options Gastroenterol. 2025, 23, 2. [Google Scholar] [CrossRef]
  21. Moyad, M.A. Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.). Curr. Urol. Rep. 2023, 24, 515–525. [Google Scholar] [CrossRef] [PubMed]
  22. Wadden, T.A.; Tronieri, J.S.; Butryn, M.L. Lifestyle Modification Approaches for Adult Obesity. Am. Psychol. 2020, 75, 235–251. [Google Scholar] [CrossRef] [PubMed]
  23. Dragonieri, S.; Portacci, A.; Quaranta, V.N.; Carratù, P.; Lazar, Z.; Carpagnano, G.E.; Bikov, A. Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Syndrome Management: A Narrative Review. Diseases 2024, 12, 224. [Google Scholar] [CrossRef] [PubMed]
  24. Hunter Gibble, T.; Cao, D.; Zhang, X.M.; Xavier, N.A.; Poon, J.L.; Fitch, A. Tirzepatide Improved Quality of Life in SURMOUNT-2. Diabetes Ther. 2025, 16, 977–991. [Google Scholar] [CrossRef] [PubMed]
  25. Dalle Grave, R. The Benefit of Healthy Lifestyle in the Era of New Medications to Treat Obesity. Diabetes Metab. Syndr. Obes. Targets Ther. 2024, 17, 227–230. [Google Scholar] [CrossRef] [PubMed]
  26. Gudzune, K.A.; Stefanski, A.; Cao, D.; Mojdami, D.; Wang, F.; Ahmad, N.; Ling Poon, J. Weight Reduction with Tirzepatide and Quality of Life. Diabetes Obes. Metab. 2025, 27, 539–550. [Google Scholar] [CrossRef] [PubMed]
Healthcare 13 03102 g001
Figure 1. Scatterplot of WEL total versus age with fitted linear trend (positive slope).
Figure 1. Scatterplot of WEL total versus age with fitted linear trend (positive slope).
Healthcare 13 03102 g001
Table 1. Baseline characteristics and tirzepatide use (N = 120).
Table 1. Baseline characteristics and tirzepatide use (N = 120).
VariableResponsen (%)
GenderMale61 (50.8)
Female59 (49.2)
Age (years), mean ± SD42 ± 13
Employment statusYes77 (64.2)
No43 (35.8)
Health insuranceNo insurance42 (35.0)
Government insurance34 (28.3)
Private insurance23 (19.2)
Employer-provided21 (17.5)
Payment method for tirzepatidePersonal income40 (33.3)
Covered by insurance35 (29.2)
Partially covered by insurance45 (37.5)
BMI (kg/m2), mean ± SD—25.74 ± 3.96
Duration of tirzepatide use<1 month27 (22.5)
1–3 months31 (25.8)
3–6 months45 (37.5)
>6 months17 (14.2)
Previous weight-loss methods triedNo104 (86.7)
Diet only8 (6.7)
Fasting4 (3.3)
Physical activities4 (3.3)
Weight loss since starting tirzepatideNone10 (8.3)
<5% of initial weight45 (37.5)
5–10%32 (26.7)
>10%33 (27.5)
Footnote: BMI = body mass index; SD = standard deviation. Percentages may not total 100% due to rounding.
Table 2. WEL item-level means and total score (higher = greater self-efficacy; scale 0–9).
Table 2. WEL item-level means and total score (higher = greater self-efficacy; scale 0–9).
ItemMean ± SD
I can resist eating when I feel anxious (stressed).4 ± 3
I can resist eating even when I have to say “No” to others.5 ± 2
I can resist eating even when others pressure me to eat.5 ± 2
I can resist eating when I feel tired.5 ± 2
I can resist eating even when high-calorie foods are available.4 ± 2
I can resist eating when I am angry.5 ± 2
I can resist eating when I feel depressed.4 ± 2
I cannot resist eating when I am at a party. 4 ± 2
I can resist eating even when I am happy and celebrating.5 ± 2
I can resist eating when I feel bored.5 ± 2
I can resist eating when I feel physically uncomfortable.5 ± 2
I can resist eating even when traveling/away from home.4 ± 2
I can resist eating even when watching TV.5 ± 2
I can resist eating even when others around me are eating.4 ± 2
I can resist eating even late at night.5 ± 3
I can resist eating after a difficult day.5 ± 2
I can resist eating when I feel lonely.4 ± 2
I can resist eating when celebrating a special occasion.5 ± 2
I can resist eating despite a strong craving for a specific food.4 ± 2
I can resist eating when I feel sad.4 ± 2
Total WEL score91 ± 34
Negatively worded item: higher raw mean reflects greater difficulty in that context. Footnote: SD = standard deviation; response range 0 (“not confident”) to 9 (“very confident”).
Table 3. WEL total by demographic and treatment characteristics.
Table 3. WEL total by demographic and treatment characteristics.
VariableCategoryMean ± SD95% CI (Mean)p-Value
GenderMale87 ± 3977.2 to 96.80.01 *
Female94 ± 2886.9 to 101.1
EmploymentYes93 ± 3984.3 to 101.70.048 *
No87 ± 2280.4 to 93.6
Health insuranceNo insurance99 ± 2691.1 to 106.9<0.001 *
Government insurance101 ± 2891.6 to 110.4
Private insurance71 ± 3357.5 to 84.5
Employer-provided80 ± 4660.3 to 99.7
Payment for tirzepatidePersonal income84 ± 3074.7 to 93.3<0.001 *
Covered by insurance93 ± 3780.7 to 105.3
Partially covered by insurance94 ± 3583.8 to 104.2
Duration of use<1 month102 ± 3588.8 to 115.2<0.001 *
1–3 months89 ± 2082.0 to 96.0
3–6 months89 ± 3578.8 to 99.2
>6 months78 ± 4656.1 to 99.9
Previous attemptsNo92 ± 3485.5 to 98.5<0.001 *
Diet only99 ± 3872.7 to 125.3
Fasting68 ± 1949.4 to 86.6
Physical activities71 ± 5022.0 to 120.0
Weight loss since tirzepatideNone92 ± 1185.2 to 98.80.003 *
<5%101 ± 3391.4 to 110.6
5–10%83 ± 3072.6 to 93.4
>10%83 ± 4169.0 to 97.0
Differences (Welch 95% CIs): Female–Male = 7·0 (−5.1 to 19.1); Employed–Unemployed = 6.0 (−4.9 to 16.9). Analytic notes: Independent-samples t-tests (two groups) and one-way ANOVA (≥3 groups); * significant at p < 0.05. SD = standard deviation.
Table 4. Correlation of WEL total with age and BMI.
Table 4. Correlation of WEL total with age and BMI.
VariablePearson r95% CI (Two-Tailed)p-Value
Age0.2390.062 to 0.4010.009
BMI0.004−0.175 to 0.1830.963
Analytic note: Pearson correlation; significance at p < 0.05.
Table 5. Summary of patient-reported experiences (selected interview prompts, n = 15).
Table 5. Summary of patient-reported experiences (selected interview prompts, n = 15).
Interview PromptSummary of Participant Responses
Satisfaction with weight-loss resultsMostly satisfied/very satisfied (visible loss, confidence); a few slower or below expectations.
Physical activity changesOften easier movement/exercise; less breathlessness/fatigue; some unchanged due to low baseline activity.
Sleep qualityFrequently improved (deeper, faster onset); some unchanged.
Energy levelsCommonly increased energy/reduced fatigue; some unchanged.
Mental health/self-confidenceOften improved mood and confidence; some unchanged/continued negative feelings.
Motivation to startDifficulty losing weight, health issues, appearance, and clinician advice.
Emotional health overallGreater self-acceptance/well-being for many; some unchanged.
Social interactionsMany reported more participation/encouragement; some reported no change.
Side effects (type/severity)Early mild–moderate GI-type symptoms; occasional severe with dose increases; some none.
Impact on daily activitiesTypically, the effects are minimal in the first week, with few reported temporary reductions in activity.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Adam, S.; Ibrahim, F.M.; Dabou, E.A.A.; Pitre, S.; Aiman, R.; AbdelSamad, S. Exploring Adults’ Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study. Healthcare 2025, 13, 3102. https://doi.org/10.3390/healthcare13233102

AMA Style

Adam S, Ibrahim FM, Dabou EAA, Pitre S, Aiman R, AbdelSamad S. Exploring Adults’ Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study. Healthcare. 2025; 13(23):3102. https://doi.org/10.3390/healthcare13233102

Chicago/Turabian Style

Adam, Shukri, Fatma M. Ibrahim, Eman Abdelaziz Ahmed Dabou, Sneha Pitre, Rania Aiman, and Shimaa AbdelSamad. 2025. "Exploring Adults’ Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study" Healthcare 13, no. 23: 3102. https://doi.org/10.3390/healthcare13233102

APA Style

Adam, S., Ibrahim, F. M., Dabou, E. A. A., Pitre, S., Aiman, R., & AbdelSamad, S. (2025). Exploring Adults’ Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study. Healthcare, 13(23), 3102. https://doi.org/10.3390/healthcare13233102

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop